AIR-STEMI
2026
Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients With Multivessel Disease (AIR-STEMI)
In 1,823 patients with STEMI and multivessel disease, angiography-derived FFR-guided non-culprit PCI reduced death, stroke, reinfarction or ischaemia-driven revascularisation compared with angiography-guided PCI.
Résultat
Efficacité: Patient-oriented composite of all-cause death, cerebrovascular accident, reinfarction or ischaemia-driven revascularisationHR 0,62 (IC à 95 % 0,47-0,83) · P < 0,001
Sécurité: Contrast-associated kidney injuryHR 0,55
En dessous de 1 en faveur de angiography-derived FFR-guided non-culprit PCI, au-dessus de 1 en faveur de angiography-guided PCI.
Taux d’événements Angiography-derived FFR-guided non-culprit PCI 8,9% vs angiography-guided PCI 13,7% (patient-oriented composite of all-cause death, cerebrovascular accident, reinfarction or ischaemia-driven revascularisation)
Également rapporté: Cardiovascular death or myocardial infarction HR 0.52 (0.37-0.73); myocardial infarction 3.8% vs 8.0% (HR 0.47), both spontaneous and procedure-related. The physiology arm used 38% fewer staged procedures, treated 45% fewer non-culprit vessels and implanted 31% less stent length.
- Sous-thème
- Physiology-guided revascularisation
- Schéma
- Prospective, international, multicentre, randomised, open-label trial with blinded adjudication of outcomes by an independent clinical events committee; 1:1 randomisation after successful culprit-lesion PCI; non-culprit PCI indicated and planned by angiography-derived FFR versus conventional angiography; follow-up censored when the last enrolled patient reaches 1 year (average about 18 months), with endpoints also assessed at 3 and 5 years
- Pertinence
- Important: l’un des piliers parmi d’autres.
- Source
- Biscaglia S, Campo G, et al. N Engl J Med. 2026; published online 29 August.doi 10.1056/nejmoa2605373
Discussion et critique
Reading physiology off the angiogram rather than crossing every lesion with a wire cut the composite by nearly two fifths, and the mechanism is visible in the procedure log: fewer staged procedures, fewer vessels treated, less stent, less contrast. Reinfarction fell for both spontaneous and procedure-related events, which argues that some of the benefit is simply harm not done. Two caveats: the trial is open-label with ischaemia-driven revascularisation in the primary endpoint, a component the operator can influence, and the FFR values came from a central core laboratory rather than the local cath lab.